

ORIGINAL CLINICAL INVESTIGATION

Open Access

# Prothrombotic profile in patients with vasospastic or non vasospastic angina and non significant coronary stenosis

Jaume Figueras\*, Jasone Monasterio, Enric Domingo, Beatriz Meneses, Elsa Nieto, Josefa Cortadellas and David Garcia-Dorado

## Abstract

**Background:** Patients with vasospastic (VA) or non vasospastic angina (NVA) without significant coronary stenosis have a reduced risk of infarction but is unclear whether or not this may be attributable to a lack of prothrombotic profile - similar to that present in patients with stable coronary artery disease (CAD).

**Methods:** Plasma levels of von Willebrand factor, total and free tissue factor pathway inhibitor, plasminogen activator inhibitor-1, and fibrinogen were analyzed in 15 patients with stable VA and 23 with NVA, all with vasoconstrictive response to acetylcholine although with different severity. Results were compared with those of 20 age-matched controls and 10 patients with CAD.

**Results:** Plasma levels of von Willebrand factor in patients with VA or NVA were higher than in controls ( $207 \pm 62$  and  $203 \pm 69\%$  vs  $121 \pm 38\%$ ,  $p < 0.001$ ) and tended to be lower than in CAD patients ( $264 \pm 65$ ,  $p = 0.145$ ). They also presented higher total tissue factor pathway inhibitor ( $123 \pm 18$  and  $111 \pm 25$  vs  $88 \pm 14$ , ng/ml  $p < 0.001$ ) and plasminogen activator inhibitor-1 levels than controls ( $51 \pm 30$  and  $52 \pm 31\%$  vs  $19 \pm 9$  ng/ml,  $p < 0.001$ ) and similar to CAD patients ( $134 \pm 23$  and  $62 \pm 31$ , respectively, ns). Moreover, free tissue factor pathway inhibitor plasma levels were lower than controls ( $18 \pm 5$  and  $17 \pm 5$  vs  $23 \pm 8$  ng/ml,  $p = 0.002$ ) and similar to CAD patients ( $14 \pm 5$ , ns). Despite this prothrombotic condition none of VA or NVA patients presented a myocardial infarction during a 9 year follow-up, an observation also reported in larger series.

**Conclusions:** During a stable phase of their disease, patients with VA or NVA present a prothrombotic profile that might eventually contribute to occurrence of myocardial infarction. The rarity of these events, however, may suggest that ill defined factors would protect these patients from coronary plaque rupture/fissure.

## Background

Endothelial dysfunction has been documented in patients with angina and non significant coronary stenosis, either vasospastic (VA)[1] or non vasospastic (NVA) - including those with syndrome X [2,3]. Overall, endothelial dysfunction appears to be a relevant event for it is often the first step of atherosclerosis [4,5] and may facilitate coronary thrombosis [6,7]. In fact, patients with atherosclerosis may present a prothrombotic state characterized by an imbalance in the thrombotic-fibrinolytic equilibrium with abnormal plasma levels of von

Willebrand factor (vWF)[8], tissue factor or tissue factor pathway inhibitor (TFPI)[9-11], plasminogen activator inhibitor-1 (PAI-1)[12-15] and fibrinogen [14,16]. In keeping with this, patients with unstable coronary artery disease and significant coronary stenosis often exhibit an abnormal coagulation profile which is associated with increased risk of coronary thrombotic events [14,17]. Nevertheless, VA and NVA patients and for unknown reasons only rarely develop a myocardial infarction [18-25]. Thus, the aim of this study was to investigate whether this reduced incidence of coronary thrombosis could in part be related to a lack of a pro-thrombotic profile despite a proven coronary endothelial dysfunction. Thus, we investigated plasma levels of relevant

\* Correspondence: 5751jfb@gmail.com

Unitat Coronària, Àrea del Cor, Laboratori d'Hemostàsia\*, Hospital General Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona. Spain

prothrombotic markers such as vWF, TFPI, PAI-1 and fibrinogen in stable patients with VA or NV. We compare these levels with those of patients with stable coronary artery disease (CAD) and with normal subjects.

## Methods

### Patients selection

Thirty eight consecutive patients with typical angina at rest responsive to sublingual nitroglycerin but without significant coronary stenosis (<50%) were selected from our chest pain out patient clinic. There were 15 with documented transient ST elevation and spontaneous and/or an ergonovine-induced coronary vasospasm categorized as VA patients, and 23 without ECG changes during pain and a negative response to ergonovine (<30% reduction in coronary lumen diameter) categorized as NVA patients. All 38 patients showed endothelial dysfunction manifested by a vasoconstrictive response to intracoronary acetylcholine which was mild to moderate (>10% <50% reduction in lumen diameter) in those with NVA, and severe (vasospasm occluding or nearly occluding the vessel) in those with VA. VA or NVA patients were clinically stable but had been hospitalized at least once in our institution for their anginal episodes >12 months prior to entering the study, showing lack of increase in myocardial necrosis markers in this hospitalization index. Patients with frank hypertension ( $\geq 160$  mmHg), left ventricular hypertrophy, bundle branch block, valvular heart disease, previous myocardial infarction or coronary revascularization procedures were excluded. Ten consecutive patients with an uncomplicated myocardial infarction (chest pain refractory to nitroglycerin, persistent ST segment elevation and elevated enzymes)  $\geq 6$  months old and without angina in the follow-up, were selected from our postmyocardial infarction outpatient clinic and constituted the CAD group.

Finally, a control group included 20 subjects from the hospital staff without apparent cardiovascular disease or major risk factors matched for age with respect to the 3 patient groups.

### Protocol

Treatment with nitrates, calcium antagonists, lipid lowering drugs or aspirin was discontinued >4 days prior to blood sampling although sublingual nitroglycerin was allowed for eventual episodes of chest pain. None of the patients, however, experienced angina during the 48 hours preceding blood sampling.

Coronary angiography was assessed by quantitative analysis (Automated coronary analysis, by Philips) by two observers unaware of the patient's condition. They evaluated the number of main epicardial coronary vessels with  $\geq 50\%$  stenosis as well as the response to i.v.

ergonovine (sequential doses 0.1 mg at 2 min intervals, up to 0.85 mg) and intracoronary acetylcholine (20, 50 and 100 micg, at 2 min intervals) in VA and NVA patients. Ejection fraction was assessed by a contrast left ventriculogram in all patients except for 4 with CAD in whom it was assessed by 2D echocardiography. The protocol was approved by the Hospital Human Ethics Committee and informed consent was obtained prior to entering the study.

### Blood sampling

Ambulatory venous blood sampling for vWF, total TFPI (t-TFPI) antigen, free TFPI (f-TFPI) antigen, PAI-1 antigen and fibrinogen was performed between 08:30 and 09:30 a.m. in a fasting condition, without vascular compression and with the patient/subject lying in bed for at least the preceding 30 minutes. They were drawn >6 months after coronary angiography. The first 3 ml of blood were discarded and 9.0 ml of blood were mixed with 1.0 ml of sodium citrate (0.13 M) for vWF, t-TFPI, f-TFPI, PAI-1 and fibrinogen measurements. Samples were then centrifuged at 3,000 g for 20 minutes at 2-8°C and the citrated tube was stored at -80°C until analyzed.

### Laboratory methods

Enzyme-linked immunosorbent assays (ELISA) were used to determine plasma concentrations of vWF, t-TFPI, f-TFPI (Asserachrom, Diagnostica Stago, Asnieres, France) and PAI-1 (Tintelize plasminogen activator inhibitor - 1, Biopool, Sweden) whereas fibrinogen plasma levels were measured by the Von Clauss coagulative method. Lower limits of detection and the co-efficients of variation were 3% and 7% for vWF, 11 ng/ml and 6.0% for t-TFPI, 3.12 ng/ml and 7% for f-TFPI, 10 ng/ml and 5.3% for PAI-1, and 1.18 g/l and 6.4% for fibrinogen, respectively.

### Statistical Analysis

The Chi-square or the Fisher test were used to compare categorical variables and the normality of distribution was assessed using a normal probability plot. Analysis of variance (ANOVA) was utilized for continuous variables with normal distribution with post hoc analysis with Bonferroni correction for multiple comparisons, and the test of Kruskal-Wallis for continuous variables with abnormal distribution. The Student T test for unpaired samples was used for intergroup differences between one time measurements, and a Pearson's coefficient correlation analysis between the different parameters and the risk factors was also carried out. The possible relationship between medicines taken and levels of laboratory parameters was assessed by a univariate analysis. The analysis was performed with SPSS 13.0, data were

expressed as percentage or mean mean  $\pm$  SD and statistical significance was set at  $p < 0.05$ .

## Results

### Demographic and angiographic data


The 4 groups showed a similar age and gender distribution although VA patients tended to present a lower proportion of women (table 1). Incidence of arterial hypertension and smoking was comparable in the 3 patients groups, and total cholesterol and high density lipoprotein levels were also similar. Patients with VA and NVA were treated mostly with nitrates and calcium channel blockers whereas those with CAD were treated more preferentially with betablockers and aspirin (table 1).

Culprit coronary stenosis  $\geq 70\%$  was documented in 5/6 patients with coronary artery disease (83%).

### Coagulation factors

vWF plasma levels were higher in VA, NVA, and CAD patients than in controls

(figure 1), being higher in 93%, 96%, and 100% of patients, respectively. t-TFPI levels were also higher (figure 2) being so in 100%, 87% and 100%, respectively). In contrast, f-TFPI levels were lower in the 3 groups (figure 3), being lower in 67%, 87%, and 90% of patients, respectively, whereas fibrinogen plasma levels tended to be higher in the 3 groups than in the control group but differences were not statistically significant. Moreover, PAI-1 plasma levels were significantly higher in VA, NVA and CAD groups than in controls (figure 4), being higher in 100%, 91% and 100% of patients, respectively, and were significantly although modestly correlated with





t-TFPI and vWF plasma levels ( $r:0.329$ ,  $p = 0.008$ , and  $r:0.299$ ,  $p = 0.015$ )

Age was correlated with vWF ( $r:0.365$ ,  $p = 0.002$ ) and cholesterol levels with t-TFPI ( $r:0.449$ ,  $p = 0.001$ ) and PAI-1 ( $r:0.361$ ,  $p = 0.004$ ). Treatment with nitrates, ACE inhibitors, beta blockers calcium channel blockers or aspirin did not seem to influence plasma levels of hemostatic parameters since in a univariate analysis patients treated with these agents showed comparable levels than those untreated. Patients treated with statins, however, had higher levels of PAI-1 ( $68.5 \pm 37.4$  vs  $44.8 \pm 25$  ng/ml,  $p = 0.030$ ) and lower levels of t-TFPI ( $114.6$

**Table 1 Clinical data of control subjects and patients with CAD, VA, or NVA (% and mean  $\pm$  SD, ANOVA test)**


	Control (20)	CAD (n:10)	VA (n:15)	NVA (n:23)	p
Age, years	54.8 $\pm$ 7.5	59.9 $\pm$ 8.9	54.5 $\pm$ 9.7	55.5 $\pm$ 9.1	0.412
Female gender, %	50	40	20	52.2	0.233
Arterial hypertension, %	0	40	53.3	56.5	0.001
Diabetes mellitus, %	0	20	0	0	0.020
Smoking, %	0	40	46.7	26	0.001
Total cholesterol, mg/dl	204 $\pm$ 31	234 $\pm$ 37	225 $\pm$ 38	223 $\pm$ 37	0.127
LDL, mg/dl	126 $\pm$ 28	158 $\pm$ 24	147 $\pm$ 23	139 $\pm$ 32	0.031
HDL, mg/dl	56 $\pm$ 12	46 $\pm$ 11	57 $\pm$ 16	56 $\pm$ 16	0.270
Triglycerides, mg/dl	108 $\pm$ 61	169 $\pm$ 95	107 $\pm$ 33	157 $\pm$ 112	0.107
Ejection fraction, %	-	55.7 $\pm$ 5.5	74.6 $\pm$ 4.4	74.1 $\pm$ 5.2	0.001
Treatment: (%)					
Nitrates	0	0	60	47.8	0.006
Beta blockers	0	70	6.7	26.1	0.003
Calcium channel blockers	0	20	86.7	56.5	0.004
ACE inhibitors	0	40.7	26.7	21.7	0.581
Aspirin	0	100	40	21.7	0.001
Statins	0	60	13.3	26.1	0.049



$\pm 23.8$  vs  $130.8 \pm 20.6$  ng/ml,  $p = 0.031$ ) than untreated patients likely because of the alluded correlation between these parameters and cholesterol levels.

#### Follow-up

During 9 years ( $108 \pm 10$  months) there were no cardiac deaths or myocardial infarction in any of the 38 patients with VA or NVA. Six VA patients (40%) and 17 with NVA (74%), however, continued to present angina although with less frequency and intensity than before entering the study.



#### Discussion

Our study documented that patients with stable VA or NVA had higher levels of vWF, t-TFPI and PAI-1 than a control group and lower levels of f-TFPI. Moreover, their values were comparable to patients with asymptomatic CAD. However, although the association of this prothrombotic profile with coronary endothelial dysfunction might have facilitated development of coronary thrombosis, none of our patients presented a myocardial infarction during an 9 years follow-up which likely suggest the concurrence of protective mechanisms.

#### vWF

Plasma levels of vWF have not been previously investigated in VA patients and 3 studies have analyzed vWF levels in patients with NVA [26-28] with variable results. Thus, Botker [26] and Kolasinska [27] found vWF levels in NVA patients similar to a control group but they represented a different cohort than ours for they had only effort angina while ours presented rest and, often, mixed angina. In contrast, Lin et al. reported increased vWF levels in NVA patients [28]. These investigators [27,28] included a much greater proportion of male patients, 64% [27] and >70% [28], than in our study and than in previous larger NVA series [20-22] also suggesting a different patient population. In addition, they did not assess - angiographically - the coronary endothelial function of their patients [26-28].

vWF is a glycoprotein that is critical for platelet adhesion and aggregation to exposed subendothelium, and plays a major role in thrombus formation [29]. In fact, increased vWF levels predict adverse cardiac events and recurrence of myocardial infarction in patients with acute coronary syndromes [14,17].

### Total and free TFPI

There are no previous studies measuring t-TFPI in patients with VA or NVA. Thus, our observation of increased plasma t-TFPI levels in these patients with respect to a control group constitute a novel finding. This is of interest since increased TFPI levels have been reported in patients with unstable angina or acute myocardial infarction [10,11] suggesting a possible causal role in coronary thrombosis. Indeed, TFPI is the most important inhibitor of tissue factor which is the principal determinant of thrombus formation after plaque rupture [30], and it is thought that increased levels represent an attempt to balance the procoagulant effects of increased tissue factor levels [9,31].

Of additional interest, our patients with VA or NVA showed lower levels of f-TFPI than control subjects. There is only one study where f-TFPI plasma levels were investigated in patients with atypical chest pain and non significant coronary stenosis, and were found to be similar to patients with stable angina [10]. In this study, however, patients were not diagnosed of angina and hence could be different than ours, who presented with typical spontaneous (rest) angina. Furthermore, there was no control group and coronary endothelial function was not assessed [10]. The significance of abnormal plasma levels of f-TFPI, however, remains controversial. Thus, while Soejima [10] reported that increased levels of f-TFPI in patients with unstable angina were associated with increased risk of unfavorable outcomes, Morange demonstrated that reduced rather than increased f-TFPI plasma level was an independent risk factor for myocardial infarction in 10,000 healthy men being an even better predictor when associated with increased levels of vWF [32]. Likewise, reduced f-TFPI levels have been recently linked to intravascular thrombosis in patients with a stroke [33] or deep vein thrombosis [34]. However, the reduced levels in our VA and NVA were not associated with development of coronary thrombosis.

### PAI-1

VA patients presented elevated PAI-1 levels and similar observations were made by Masuda [35] and Yamaguchi [36]. In contrast, Misumi et al. showed increased PAI-1 levels in VA patients but only following coronary spasm and not at baseline [37]. Increased PAI-1 levels were also documented in our NVA patients and, in the only existing report [27], NVA patients tended also to show higher plasma levels than a control group, particularly during exercise, although the differences reached no statistical significance [27]. This study, however, failed to provide angiographic evidence of endothelial dysfunction and had an unusually high proportion of males, 64% [27].

PAI-1 is released by activated platelets and endothelial cells and effectively inhibits fibrinolysis [38] by neutralizing tissue plasminogen activator. Increased plasma levels have been found in patients with unstable angina or acute myocardial infarction [15,35] and seem to precede occurrence or recurrence of myocardial infarction [12-14].

### Endothelial dysfunction and myocardial infarction

Despite reduced f-TFPI and increased vWF and PAI-1 levels - all apparent procoagulant factors and markers of endothelial dysfunction - myocardial infarction did not occur in our series and has not been a frequent finding in the follow-up of larger series of patients with VA without significant stenosis [18,19] or patients with NVA [20-22]. In some contemporary series, however, adverse outcomes have been more frequently reported in NVA patients with proven endothelial dysfunction [23-25].

Development of a thrombotic coronary occlusion in CAD patients appears to be independent of the severity of coronary stenosis since it often occurs in non significantly stenosed vessels [8,39] and may even develop over an endothelial erosion [7]. Thus, since patients with VA or NVA often share conventional risk factors and some degree of atherosclerosis with those with CAD, it is conceivable that further derangements in their procoagulant profile could supervene during an unstable phase - intense emotional stress [40] - thereby enhancing the risk of coronary thrombosis. In this respect, Buggiardini has recently reported a low incidence of myocardial infarction during a 10 year follow-up in 42 patients with NVA, 5%, but that was higher in those with a vasoconstrictive response to acetylcholine [25]. By and large, however, the remarkably low incidence of thrombotic events despite the correlation between cholesterol levels and t-TFPI and PAI-1 shown in our study points to protective mechanisms - possibly genetically mediated - against development of complicated atherosclerotic plaques. Indeed, in view of the reduced use of statins in VA and NVA patients it is unlikely that cholesterol levels and their positive interaction with prothrombotic factors would decline in the follow-up. Similarly, the infrequent use of platelet anti-aggregants would further lower the possibility of a pharmacological protection.

### Limitations

Intracoronary ultrasonographic studies to clarify the proportion of NVA patients with a completely normal vascular walls, intimal thickening, or small atherosclerotic plaques [41], were not available in our study. Nevertheless, all these patients showed a <50% culprit stenosis, were well characterized clinically, and had a

proper assessment of their coronary endothelial dysfunction. We admit also that the reduced sample size as well as the lack of measurements of prothrombotic markers in the follow-up limits the clinical implications with respect to the risk of coronary thrombotic events although follow-up was long and larger series had shown similar results [18-21]. In addition, even though we attempted to avoid blood sampling during inflammatory processes given their potential interaction with coagulation parameters, we can not totally rule out such an effect.

## Conclusions

Our findings indicate that stable patients with VA or NVA and angiographically documented coronary endothelial dysfunction present increased levels of vWF, t-TFPI and PAI-1, and reduced levels of f-TFPI. They contribute to the understanding of these poorly defined syndromes and suggest that this association of coronary endothelial dysfunction with a prothrombotic state might eventually facilitate coronary thrombosis, particularly under stressful conditions [40]. However, the lack of development of myocardial infarction - also seen in larger series [18-22] - would confirm that this is an unusual complication. Moreover, since less than 1/3 of our patients were treated with statins and platelet antiaggregants, it is tempting to speculate that they were *naturally* (genetically) protected from coronary plaque rupture and subsequent thrombosis.

## List of abbreviations

VA: vasospastic angina; NVA: non vasospastic angina; CAD: coronary artery disease; vWF: von Willebrand factor; t-TFPI: total tissue factor pathway inhibitor; f-TFPI: free tissue factor pathway inhibitor; PAI-1: plasminogen activator inhibitor-1.

## Acknowledgements and funding

This study was in part financially supported by a grant from the Fundació Recerca Biomèdica i Docència Hospital Vall d'Hebron (PR, HG 84/98), Barcelona, Spain, and by a grant from Redes Temáticas de Investigación Cooperativa (RECAVA, C03/01).

## Authors' contributions

JF: has contributed to conception and design, acquisition of data, analysis and interpretation of data; has also been involved in drafting the manuscript and has given final approval of the version to be published.

JM: has made substantial contributions to conception and design, and has participated in the analysis and interpretation of data and revising it critically for important intellectual content. She has also given final approval of the version to be published.

ED: has made substantial contributions to conception, design, acquisition of data, analysis and interpretation of data, and has been involved in revising the manuscript critically for important intellectual content. He has also given final approval of the version to be published.

BM: has made substantial contributions to acquisition of data, and has been involved in drafting the manuscript and revising it critically for important intellectual content. She has also given final approval of the version to be published.

EN: has made substantial contributions to acquisition, analysis and interpretation of data. She has also been involved in revising the manuscript

critically for important intellectual content and has given final approval of the version to be published.

JC: has made substantial contributions to acquisition, analysis and interpretation of data. She has also been involved in revising the manuscript critically for important intellectual content and has given final approval of the version to be published.

DGD: has made substantial contributions to analysis and interpretation of data. He has also been involved in revising the manuscript critically for important intellectual content and has given final approval of the version to be published.

## Competing interests

The authors declare that they have no competing interests.

Received: 5 October 2010 Accepted: 27 May 2011

Published: 27 May 2011

## References

1. Miwa K, Goto M, Lee JD, Matsuyama I, Shimizu H, Kato T, Hara A, Nakamura T: **Supersensitivity of coronary arteries in variant angina to spasm induced by intracoronary acetylcholine.** *Am J Cardiol* 1988, **61**:77-82.
2. Quyyumi AA, Cannon RO, Panza JA, Diodati J, Epstein SE: **Endothelial dysfunction in patients with chest pain and normal coronary arteries.** *Circulation* 1992, **86**:1864-1871.
3. Egashira K, Inou T, Hirooka Y, Yamada A, Urabe Y, Takeshita A: **Evidence of impaired endothelium-dependent vasodilation in patients with angina pectoris and normal coronary angiograms.** *N Engl J Med* 1993, **328**:1659-1664.
4. Ross R: **Atherosclerosis: an inflammatory disease.** *N Engl J Med* 1999, **340**:115-126.
5. Verma S, Anderson TJ: **Fundamentals of endothelial function for the clinical cardiologist.** *Circulation* 2002, **105**:546-549.
6. Fuster V, Badimon L, Badimon JJ, Chesebro JH: **The pathogenesis of coronary artery disease and the acute coronary syndromes.** *N Engl J Med* 1992, **326**:210-218, 242-250.
7. Kragel AH, Gertz SD, Roberts WC: **Morphologic comparison of frequency and types of acute lesions in the major epicardial coronary arteries in unstable angina pectoris, sudden coronary death and acute myocardial infarction.** *J Am Coll Cardiol* 1991, **89**:36-44.
8. Hoffmeister A, Rothenbacher D, Bärner U, Fröhlich M, Brenner H, Hombach V, Kjoenig W: **Role of novel markers of inflammation in patients with stable coronary heart disease.** *Am J Cardiol* 2001, **87**:262-66.
9. Falciani M, Gori AM, Fedi L, Chiarugi L, Simonetti I, Dabizzi RP, Prisco D, Pepe G, Abbate R, Gensini GF, Neri Serneri GG: **Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease patients.** *Thromb. Haemostasis* 1998, **79**:495-499.
10. Soejima H, Ogawa H, Yasue H, Kikita K, Nishiyama K, Misumi K, Takazoe K, Miyao Y, Yoshimura M, Kugiyama K, Nakamura S, Tsuji I, Kumeda K: **Heightened tissue factor associated with tissue factor pathway inhibitor and prognosis in patients with unstable angina.** *Circulation* 1999, **99**:2908-2913.
11. Golino P, Ravera A, Ragni M, Cirillo P, Piro O, Chiarello M: **Involvement of tissue factor pathway inhibitor in the coronary circulation in patients with acute coronary syndromes.** *Circulation* 2003, **108**:2864-2869.
12. Hamsten A, De Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blombäck M, Wiman B: **Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction.** *Lancet* 1987, **2**:3-9.
13. Munkvad S, Gram J, Jespersen J: **A depression of active tissue plasminogen activator in plasma characterizes patients with unstable angina pectoris who develop myocardial infarction.** *Eur Heart J* 1990, **11**:525-528.
14. Wiman B, Anderson T, Hallqvist J, Reuterwall C, Ahlbom A, de Faire U: **Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart epidemiology program (SHEEP) study.** *Arterioscler Thromb Vasc Biol* 2000, **20**:2019-2023.
15. Figueras J, Monasterio Y, Lidón RM, Nieto E, Soler Soler J: **Thrombin formation and fibrinolytic activity in patients with acute myocardial**

- infarction or unstable angina. In-hospital course and relationship with recurrent angina at rest. *J Am Coll Cardiol* 2000, **36**:2036-2043.
16. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC: Hemostatic factors and the risk of myocardial infarction and sudden death in patients with angina pectoris. European concerted action on thrombosis and disabilities angina pectoris study group. *N Engl J Med* 1995, **332**:635-641.
  17. Jansson J, Nilsson TK, Johnson O: von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. *Br Heart J* 1991, **66**:351-5.
  18. Yasue H, Takizawa A, Nagao M, Nishida S, Horie M, Kubota J, Omote S, Takaoka K, Okumura K: Long-term prognosis for patients with variant angina and influential factors. *Circulation* 1988, **78**:11-9.
  19. Nakamura M, Takeshita A, Nose Y: Clinical characteristics associated with myocardial infarction, arrhythmias, and sudden death in patients with vasospastic angina. *Circulation* 1997, **75**:1110-1116.
  20. Kemp HG, Kronmal RA, Vlietstra RE, Frye RL: Seven year survival of patients with normal or near normal coronary angiograms: A CASS Registry Study. *J Am Coll Cardiol* 1986, **7**:479-483.
  21. Lichtlen PR, Bargheer K, Wenzlaff P: Long-term prognosis of patients with angina-like chest pain and normal coronary angiographic findings. *J Am Coll Cardiol* 1995, **25**:1013-1018.
  22. Kaski JC, Rosano GM, Collins P, Nihoyannopoulos P, Maseri A, Poole-Wilson PA: Clinical characteristics and left ventricular function. Long-term follow-up study. *J Am Coll Cardiol* 1995, **25**:807-814.
  23. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A: Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. *Circulation* 2000, **101**:948-954.
  24. Widlansky ME, Gokce N, Keaney JF: The clinical implications of endothelial dysfunction. *J Am Coll Cardiol* 2003, **42**:1149-1160.
  25. Bugiardini R, Manfrini O, Pizzi c, Fontana F, Morgagni G: Endothelial function predicts future development of coronary artery disease. *Circulation* 2004, **109**:2518-2523.
  26. Botker HE, Ingerslev J: Plasma concentrations of von Willebrand Factor in patients with angina pectoris secondary to atherosclerosis or cardiac syndrome X. *Thromb Res* 2000, **97**:519-523.
  27. Kolasinska-Kloch W, Lesniak W, Kiee-Wilk B, Malczewska-Malee M: Biochemical parameters of endothelial dysfunction in cardiologic syndrome X. *Scand J Clin Lab Invest* 2002, **62**:7-13.
  28. Lin C, Lin W, Leu H, Wu T, Chen J: Differential monocellular cell activity and endothelial inflammation in coronary artery disease and cardiac syndrome X. *Int J Cardiol* 2003, **89**:53-62.
  29. Cines DB, Pollak ES, Buck CA, Loscalzo J, Zimmerman GA, Mc Ever RP, Pober JS, Wick TM, Konkle BA, Schwartz BS, Barnathan ES, McCrae KR, Hugh BA, Schmidt AM, Stern DM: Endothelial cells in physiology and in the pathophysiology of vascular disorders. *Blood* 1998, **91**:3527-3561.
  30. Annex BH, Denning SM, Channon KM, Sketch MH, Stack RS, Morrissey JH, Peters KG: Differential expression of tissue factor protein in directional atherectomy specimens from patients with stable and unstable coronary syndromes. *Circulation* 1995, **91**:619-622.
  31. Drew AF, Davenport P, Apostolopoulos J, Tipping PG: Tissue factor pathway inhibitor expression in atherosclerosis. *Lab Invest* 1997, **77**:291-298.
  32. Morange PE, Simon C, Alessi MC, Luc G, Arveiler D, Ferrieres J, Amouyel P, Evans A, Ducimetiere P, Juhan-Vague I: Endothelial cell markers and the risk of coronary heart disease: the Prospective epidemiologic Study of Myocardial Infarction (PRIME) study. *Circulation* 2004, **109**:1343-1348.
  33. Hoke M, Kyrle PA, Minar E, Bialonczyk C, Hirschl M, Schneider B, Kollars M, Weltermann A, Eichinger S: Tissue factor pathway inhibitor and the risk of recurrent venous thromboembolism. *Thromb Haemost* 2005, **94**:787-90.
  34. Adams MJ, Thom J, Hankey GJ, Baker R, Gilmore G, Staton J, Eikelboom JW: The tissue factor pathway in ischemic stroke. *Blood Coagul Fibrinolysis* 2006, **17**:527-32.
  35. Masuda T, Yasue H, Ogawa H, Misumi I, Sakamoto T, Okubo H, Miyao Y: Plasma plasminogen activator inhibitor activity and tissue plasminogen activator levels in patients with unstable angina and those with coronary vasospastic angina. *Am Heart J* 1992, **124**:314-319.
  36. Yamaguchi H, Homma Y, Handa S: Biochemical markers of vasospastic coronary artery disease. *Nutr Metab Cardiovasc Dis* 2003, **13**:365-371.
  37. Misumi I, Ogawa H, Masuda T, Sakamoto T, Okumura K, Yasue H: Increased plasma plasminogen activator inhibitor activity after coronary spasm. *Int J Cardiol* 1993, **41**:21-29.
  38. Vaughan DE: Plasminogen activator inhibitor-1 and the calculus of mortality after myocardial infarction. *Circulation* 2003, **108**:376-377.
  39. ECAT Angina Pectoris Study Group: ECAT Angina Pectoris Study: baseline association of haemostatic factors with extent of coronary arteriosclerosis and other coronary risk factors in 3000 patients with angina pectoris undergoing coronary angiography. *Eur Heart J* 1993, **14**:8-17.
  40. Wittstein IS, Thiemanndr DR, Lima JAC, Baughman KL, Schulman SP, Gerstenblith G, Wu KC, Rade JJ, Bivalacqua TJ, Champion HC: Neurohumoral features of myocardial stunning due to sudden emotional stress. *N Engl J Med* 2005, **352**:539-548.
  41. Wiedermann JG, Schwartz A, Apfelbaum M: Anatomic and physiologic heterogeneity in patients with syndrome X: An intravascular ultrasound study. *J Am Coll Cardiol* 1995, **25**:1301-1317.

doi:10.1186/1477-9560-9-10

**Cite this article as:** Figueras et al.: Prothrombotic profile in patients with vasospastic or non vasospastic angina and non significant coronary stenosis. *Thrombosis Journal* 2011 **9**:10.

**Submit your next manuscript to BioMed Central and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
www.biomedcentral.com/submit

